Antitumoral effect of arsenic compound, sodium metaarsenite (KML001), on multiple myeloma cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seo Ju | - |
dc.contributor.author | Kim, Eun Shil | - |
dc.contributor.author | Kim, Sujong | - |
dc.contributor.author | Uhm, Jieun | - |
dc.contributor.author | Won, Young Woong | - |
dc.contributor.author | Park, Byeong Bae | - |
dc.contributor.author | Choi, Jung Hye | - |
dc.contributor.author | Lee, Young Yiul | - |
dc.date.accessioned | 2021-07-30T05:17:17Z | - |
dc.date.available | 2021-07-30T05:17:17Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2017-12 | - |
dc.identifier.issn | 1019-6439 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/3975 | - |
dc.description.abstract | KML001 (sodium metaarsenite; NaAs2O3) is known to have antitumor activity against a variety of cancers. In this study, we examined its effect on multiple myeloma (MM). KML001 reduced the growth of all MM cell lines examined with an IC50 of 5x10(-8) M. Exposure to KML001 (5x10(-8) M) decreased levels of cyclins A/B1/D1/E1, CDK2/4/6 in U266 cells and increased the p21 and p27 levels. Furthermore, p21 became bound to CDK2/4/6, resulting in a reduction of CDK2/4/6 kinase activity. The cleaved forms of Bcl-2, and caspases-3, -8 and -9 were detected, and the anti-apoptotic molecule, Bax, also increased. Activation of STAT1/3, NF-kappa B (p65 and p50 subunits), pAKT and pERK decreased, and p-PTEN increased. There was also a significant reduction of hTERT at 12 h and upregulation of gamma-H(2)A(X) and CHK1/2 molecules at 24 h. Thus, KML001 appears to have antitumor activity against MM by inhibiting various oncogenic signaling pathways. It may be useful for treating MM. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | SPANDIDOS PUBL LTD | - |
dc.title | Antitumoral effect of arsenic compound, sodium metaarsenite (KML001), on multiple myeloma cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Uhm, Jieun | - |
dc.contributor.affiliatedAuthor | Won, Young Woong | - |
dc.contributor.affiliatedAuthor | Park, Byeong Bae | - |
dc.contributor.affiliatedAuthor | Choi, Jung Hye | - |
dc.identifier.doi | 10.3892/ijo.2017.4161 | - |
dc.identifier.scopusid | 2-s2.0-85033433030 | - |
dc.identifier.wosid | 000416685600011 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF ONCOLOGY, v.51, no.6, pp.1739 - 1746 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF ONCOLOGY | - |
dc.citation.title | INTERNATIONAL JOURNAL OF ONCOLOGY | - |
dc.citation.volume | 51 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 1739 | - |
dc.citation.endPage | 1746 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | TELOMERASE | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordPlus | APOPTOSIS | - |
dc.subject.keywordPlus | PROSTATE | - |
dc.subject.keywordAuthor | multiple myeloma | - |
dc.subject.keywordAuthor | KML001 | - |
dc.subject.keywordAuthor | cell cycle | - |
dc.subject.keywordAuthor | cell signaling | - |
dc.subject.keywordAuthor | telomere | - |
dc.identifier.url | https://www.spandidos-publications.com/10.3892/ijo.2017.4161 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.